SOURCE: Revolutions Medical Corp.

September 01, 2009 08:45 ET

Revolutions Medical Significantly Bolsters Capital Markets Team With Appointments of Prominent Transfer Agent and Legal Counsel

Transfer Agent: American Stock Transfer & Trust Company

Legal Counsel: Joseph M. Lucosky, Anslow & Jaclin, LLP

MOUNT PLEASANT, SC--(Marketwire - September 1, 2009) - Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB: RMCP), producers of the Rev Vac safety syringe, today announced that is has strengthened its public company profile with the appointments of prominent firms American Stock Transfer & Trust Company, LLC and Anslow & Jaclin, LLP (transfer agent and legal counsel, respectively).

American Stock Transfer & Trust Company, LLC ("AST") ( will manage all stock transfer activities for Revolutions Medical's registered shareholders effective August 31, 2009.

American Stock Transfer & Trust Company, the nation's largest independent stock transfer agent, is headquartered in New York. Founded in 1971, AST services over 2,800 public companies (including such firms as Microsoft, Coca-Cola and Dell) and maintains approximately 6,000 issues. All aspects of service, including investor relations, reconciliation, corporate actions, print and mail functions are facilitated in one location, owned by AST.

In addition, Revolutions Medical Corporation has hired Joseph M. Lucosky, a partner in the law firm of Anslow & Jaclin, LLP as outside general and securities counsel. Mr. Lucosky's experience has spanned a wide variety of industries, from core manufacturing to biotech, high-tech and clean-tech, and has been both national and international in scope. Anslow & Jaclin ( is a fixture in the micro cap industry, and is consistently ranked as one of its leading firms.

"Changing to one of the largest transfer agents in the world with the latest shareholder technologies was very important to us as we move towards a revenue driven company," stated Ron Wheet, Revolutions Medical CEO. "AST's focus on quality service and technology, along with their willingness to work with us in developing customized solutions, convinced us that AST was the best equipped to expertly support our investors. Also, the addition of the legal experience Joe Lucosky and the Anslow & Jaclin legal team will bring to our company will be of monumental help to our management group."

"To Anslow & Jaclin, the firm has deservedly built one of the strongest names in the small public issuer space. Joe Lucosky in particular has demonstrated a unique ability to help companies like Revolutions Medical accomplish their goals and get to the next level, and his technical skills and work ethic are well known to industry insiders. We believe that we now have the best possible representation in both aspects of our public profile, and together these two appointments form the foundation for capital markets success."

To be added to the Revolutions Medical investor email list, please email with RMCP in the subject line.

About Revolutions Medical Corporation (

Revolution Medical's products include the Rev Vac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. Revolutions Medical also provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software includes sorting of images, color, 3D and automatic segmentation of images.


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information